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MouseFree radicals play a major role in gliomas. By combining immuno-spin-trapping (IST) and molecular magnetic
resonance imaging (mMRI), in vivo levels of free radicals were detected within mice bearing orthotopic GL261
gliomas. The nitrone spin trap DMPO (5,5-dimethyl pyrroline N-oxide) was administered prior to injection of an
anti-DMPO probe (anti-DMPO antibody covalently bound to a bovine serum albumin (BSA)–Gd (gadolinium)-
DTPA (diethylene triamine penta acetic acid)–biotin MRI contrast agent) to trap tumor-associated free radicals.
mMRI detected the presence of anti-DMPO adducts by either a signiﬁcant sustained increase (p b 0.001) in MR
signal intensity or a signiﬁcant decrease (p b 0.001) in T1 relaxation, measured as %T1 change. In vitro assessment
of the anti-DMPO probe indicated a signiﬁcant decrease (p b 0.0001) in T1 relaxation in GL261 cells that were ox-
idatively stressed with hydrogen peroxide, compared to controls. The biotin moiety of the anti-DMPO probe was
targeted with ﬂuorescently-labeled streptavidin to locate the anti-DMPO probe in excised brain tissues. As a neg-
ative control a non-speciﬁc IgG antibody covalently bound to the albumin–Gd-DTPA–biotin construct was used.
DMPO adducts were also conﬁrmed in tumor tissue from animals administered DMPO, compared to non-tumor
brain tissue. GL261 gliomas were found to have signiﬁcantly increased malondialdehyde (MDA) protein adducts
(p b 0.001) and 3-nitrotyrosine (3-NT) (p b 0.05) compared to normal mouse brain tissue, indicating increased
oxidized lipids and proteins, respectively. Co-localization of the anti-DMPO probe with either 3-NT or 4-
hydroxynonenal was also observed. This is the ﬁrst report regarding the detection of in vivo levels of free radicals
from a glioma model.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
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Understanding the extent and timing of in vivo events triggered by
free radicals is important to consider, as these are major determinants
of disease evolution and progression. By combiningmolecular magnetic
resonance imaging (mMRI) and immuno-spin trapping (IST) technolo-
gies it is possible for the ﬁrst time tomonitor levels of in vivo radicals in
rodent glioma models.
Numerous studies indicate that oxidative stress, a result of an imbal-
ance in levels of ROS/RNS and anti-oxidative defense systems, plays a
crucial role in cancer. Free radicals are involved and/or are the causal
agents in several cancers, including gliomas. ROS/RNS may directly oxi-
dize nucleic acids, proteins, carbohydrates and lipids, causing intracellu-
lar and intercellular perturbations in homeostasis, including DNA
mutations and interference with DNA repair [1]. High concentrations
of lipid-derived electrophilic products resulting from the oxidation pro-
cess readily react with proteins, DNA and phospholipids, generating
intra- and intermolecular toxic covalent adducts that lead to the propa-
gation and ampliﬁcation of oxidative stress [1].
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be trapped by 5,5-dimethyl-1-pyrroline N-oxide (DMPO) to form
DMPO-radical adducts, which can then be further tagged by IST, ameth-
od that utilizes an antibody against DMPO-adducts [2–5]. It would be of
paramount importance if the formation of oxidation products could be
assessed in vivo, allowing the study of speciﬁc cause–consequence rela-
tionships from speciﬁc oxidative events. This approachwould allow sci-
entists to correlate the detection of in situ oxidative stress markers with
speciﬁc longitudinal pathological conditions associated with glioma
tumor growth.
In a novel approach, we have combined the desired morphological
image resolution of mMRI with a Gd-DTPA–albumin-based contrast
agent for signal detection with the speciﬁcity of an antibody for DMPO
nitrone adducts (anti-DMPO probe), to detect in vivo free radicals (see
Fig. 1). In this study, the anti-DMPO probe was used to assess heteroge-
neous free-radical formation within orthotopic mouse gliomas.2. Methods
2.1. Syntheses of DMPO-speciﬁc MRI contrast agents
To recognize the DMPO-radical adducts, a mouse monoclonal anti-
DMPO antibody bound to a contrast agent was used. Themacromolecu-
lar contrast material, biotin–BSA–Gd-DTPA, was prepared using a mod-
iﬁcation of the method of Dafni et al. [6]. The biotin moiety in the
contrast material was added to allow histological localization. Biotin–
BSA–Gd-DTPA was synthesized as described in Towner et al. [7]. AFig. 1.Approach for combined in vivomMRI and IST. (A) Anti-DMPO–albumin–Gd-DTPA–
biotin mMRI probe (anti-DMPO probe). (B) Immuno-spin trapping of free radicals (•R)
with anti-DMPO mMRI probe. DMPO is injected i.p. to trap free radicals and generate
nitrone-radical (R) adducts. Anti-DMPO is injected i.v. to target nitrone-R adducts,
which can be visualized by mMRI.solution of biotin–BSA–Gd-DTPA was added directly to the solution
of antibody (anti-DMPO, 200 μg/mL) for conjugation through a sulfo-
NHS (N-succinimidyl-S-acetylthioacetate)–EDC (N-succinimidyl 3-(2-
pyridyldithio)-propionate) link between albumin and antibody ac-
cording to the protocol of Hermanson [8]. Sulfo-NHS was added to the
solution of biotin–BSA–Gd-DTPA and EDC. This activated solution was
added directly to the antibody (anti-DMPO, 20 μg/mL) for conjugation.
The mixture was left to react for at least 2 h at 25 °C in the dark. The
product was lyophilized and subsequently stored at 4 °C and
reconstituted to the desired concentration for injections in phosphate
buffer saline (PBS). The ﬁnal amount of the product, anti-DMPO–
biotin–BSA–Gd-DTPA (anti-DMPO probe), that was injected into the
mice is estimated to be 20 μg anti-DMPO Ab/injection, and 10 mg
biotin–BSA–Gd-DTPA/injection. The estimated molecular weight of the
anti-DMPO–biotin–BSA–Gd-DTPA probe is estimated to be 232 kDa.
As a control, normal mouse-IgG (obtained from a healthy mouse
population; Alpha Diagnostic International, San Antonio, TX, USA)
conjugated to biotin–BSA–Gd-DTPA (control IgG contrast agent) was
synthesized by the same protocol to generate an isotype contrast agent.2.2. In vitro characterization of anti-DMPO probe
Vials were prepared containing either GL261 mouse glioma cells
(106) alone, GL261 cells with hydrogen peroxide (H2O2) and
DMPO, GL261 cells with DMPO + anti-DMPO probe, GL261 cells
with H2O2 + DMPO + anti-DMPO probe, or water (no cells). Cells
(mouse GL261 cells) were grown in ﬂasks in complete growthmedium
(DMEM Media with 10% fetal bovine serum (FBS), Invitrogen, Grand
Island, NY, USA) to conﬂuency. Two to three hours before treatment,
the growth medium was replaced with serum-free medium. DMPO
(40 mM)was added to appropriate vials, and after 15 min equilibrium,
H2O2 (50 μM) was added. In the samples that contained all compo-
nents, the anti-DMPO probe was added (2 μg, based on antibody calcu-
lation), and cells were incubated for 45 min. Following incubation, cells
were collected, washedwith PBS, centrifuged (500 rpm), and the pellet
was resuspended in PBS for MR imaging. Each measurement was re-
peated 4 times per treatment group.2.3. Animal experiments
All animal experiments were conducted in accordance with the Na-
tional Institutes of Health animal use and welfare guidelines, and with
the authorization of the Oklahoma Medical Research Foundation insti-
tutional animal ethics committee.2.3.1. Intracranial mouse brain tumor model
As a model for orthotopic intracranial brain tumors, a GL261 mouse
gliomamodel was used (n = 8). Mouse glioma cells (GL261) were im-
planted intracerebrally in C57BL6/J mice. The heads of anesthetized
mice were immobilized (stereotaxic unit; Kopf Instruments, Tujunga,
CA), and with aseptic techniques, a 1 mm burr hole was drilled in the
skull 1 mm anterior and 2 mm lateral to the bregma on the left side. A
20 μL gas-tight Hamilton syringe was used to inject 2 × 104 GL261
cells (in 10 μL of PBS) into the left frontal lobe at a depth of 1.5 mm rel-
ative to the dural surface in a stereotaxic unit. The cell lines were
maintained and expanded immediately prior to inoculation. Following
injection, the skin was closed with surgical sutures. The anti-DMPO
probe was administered at 19 days following cell implantation. Mice
(n = 4)were treatedwithDMPO for 3 days starting at day 16 following
implantation of cells, and prior to the administration of the anti-DMPO
probe. For an isotype contrast agent control, GL261 glioma-bearing
mice (n = 4) were treated with DMPO, but were administered a non-
speciﬁc mouse IgG-albumin–Gd-DTPA–biotin (IgG) contrast agent.
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DMPO (25 μL or 1.8 mMin saline; 125 μL volume)was administered
i.p. 3× daily (every 6 h) for 3 days. DMPO administration started at day
16 following intracerebral implantation of GL261 glioma cells.
2.5. Magnetic resonance techniques
MR experiments were carried out under general anesthesia (1–2%
Isoﬂurane, 0.8–1.0 L/min O2). MRI experiments were conducted on a
Bruker Biospec 7.0 Tesla/30 cm horizontal-bore imaging spectrometer.
Anesthetised (2% Isoﬂurane) restrained mice were placed in an MR-
compatible cradle and inserted into a MR probe, and their brains were
localized by MRI. Images were obtained using a Bruker S116 gradient
coil (2.0 mT/m/A), a 72 mm quadrature multi-rung RF coil, and mouse
surface head coil. Mouse brainswere imaged in vivo at various intervals
(at 7, 10 and 14 days following cell implantation prior to administration
of the anti-DMPO probe at day 21) and tumors as small as 0.05 mm in
diameter could be detected. Multiple brain 1H MR image slices were
taken in the transverse plane using a spin echo multislice sequence
(repetition time (TR) 0.8 s, echo time (TE) 23 ms, 128 × 128 matrix, 4
steps per acquisition, 3 × 4 cm2 ﬁeld of view, 1 mm slice thickness).
Mouse brains were imaged at 0 (pre-contrast), 20, 40, 60, 120
and 180 min intervals post-probe or -contrast agent injection. Mice
were injected intravenously with anti-DMPO or non-immune-IgG anti-
bodies tagged with a biotin–Gd-DTPA–albumin-based contrast agent
(200 μL/kg; 1 mg antibody/kg; 0.4 mmol Gd+3/kg) [7]. T1-weighted
images were obtained using a variable TR (repetition time) RARE se-
quence (TR 200, 400, 800, 1200 and 1600 ms; TE 15 ms, FOV
2 × 2 cm2, matrix 256 × 256, slice thickness 0.5 mm, 2 slices, and 2
steps per acquisition). Pixel-by-pixel relaxationmapswere reconstructed
from a series of T1-weighted images using a nonlinear two-parameter
ﬁtting procedure. The T1 relaxation value of a speciﬁed region-of-
interest (ROI) was computed from all the pixels in the ROI by the
following equation [9] (processed by ParaVision 4.0, Bruker): S(TR) =
S0(1 − e−TR / T1), where TR is the repetition time (units: ms), S0 is the
signal intensity (integer machine units) at TR≫ T1 and TE = 0,
and T1 is the constant of the longitudinal relaxation time (units:
ms). Relative probe (contrast agent) concentrations, C (units: M),
were calculated for each of the selected ROIs using the following for-
mula [9]: C ∞ [1 / T1(after) − 1 / T1(before)], where 1 / T1 (after) is
the T1 rate taken at different time points after injection of probes,
and 1 / T1 (before) is the T1 rate taken before injection of probes.
2.6. Excised brain tissues
Cardiac perfusion with PBS was performed while the mice were
under anesthesia (Isoﬂurane), and then the heads were cut off using a
guillotine. The skin and the muscles were removed from the head.
Then the bones on the top of the head were carefully removed, from
the cerebellum to the olfactory bulb through the bregma, and from
one side of the head to the other side. The ear bones were carefully
extracted from the brain; the optic chiasm and the olfactory bulb were
excised in order to extract the brain. A transverse cut was then
performed to get samples for ﬂuorescence microscopy/immunohisto-
chemistry (IHC) analyses or biochemical (ELISA [enzyme linked immu-
nosorbent assay]) assays in the glioma and normal brain regions.
2.7. Immunohistochemistry
For ﬂuorescence microscopy/IHC assessments, the brains were ex-
cised, and they were cut and ﬁxed in Z-ﬁxative (Zinc Formalin: Formal-
dehyde 3.7%, Zinc Sulfate). The tissues were then washed with PBS
and incubated with 15% sucrose before embedding in Optimal Cutting
Temperature (O.C.T.) compound and frozen in liquid nitrogen. Im-
munohistochemisty (IHC) staining of DMPO-nitrone adducts wasdone by incubating tissue sections with anti-DMPO antibodies conju-
gated to Cy3 in phosphate-buffered saline containing 0.1% v/v saponin.
To target the Gd-based anti-DMPO probe in excised ﬁxed tissues,
cryosections were stained with either streptavidin-FITC (ﬂuoresce-
in isothiocyanate) or Cy3-labeled streptavidin (Jackson Immuno
Research Labs, West Grove, PA, USA), which can bind to the biotin
moiety of the albumin–Gd-DTPA–biotin contrast agent within the
target tissue. For IHC staining of 3-nitrotyrosine (3-NT), a rabbit
anti-nitrotyrosine antibody (Sigma, St. Louis, MO, USA) was used.
For IHC staining of 4-hydroxy-2-nonenal (4-HNE), a rabbit anti-
HNE antibody (Alpha Diagnostic International, San Antonio, TX,
USA) was used. For ﬂuorescence imaging of 3-NT or 4-HNE IHC a
donkey anti-rabbit FITC secondary antibody (Jackson Immuno Re-
search Laboratories) was used. Stained tissue slices were examined
with a Nikon C1 confocal laser scanning microscope (Nikon Instru-
ments, USA).
2.8. Tissue homogenates for oxidation assays
For preparation of tissue homogenates for ELISA assays, tissue sam-
ples were rinsed with PBS, homogenized in PBS and stored overnight
at−20 °C. After two freeze–thaw cycles were performed to break cell
membranes, the homogenates were centrifuged for 5 min at 5000 ×g
(2–8 °C). The supernatants were removed immediately and assayed.
Protein concentrations were measured using a Pierce(R) Microplate
BSA (bicinchoninic acid) Protein Assay Kit (Pierce Biotechnology, Rock-
ford, IL, USA) using BSA as a standard.
2.9. Lipid oxidation
The OxiSelectTM MDA adduct ELISA kit (Cell Biolabs, Inc., San Diego,
CA, USA) was used for detection and quantiﬁcation of MDA
(malondialdehyde)-protein adducts in ex vivo mouse GL261 glioma
and normal brain tissues as a measure of lipid peroxidation, similar to
a study by El Ali et al. [10]. In brief, BSA (bovine serum albumin) stan-
dards and protein samples (10 μg/mL) were adsorbed onto a 96-well
plate for 2 h at 37 °C. Then the MDA-protein adducts present in the
sample or standard were probed with an anti-MDA antibody, followed
by an HRP (horseradish peroxidase) conjugated secondary antibody.
The quantity of MDA adduct in protein samples was determined by
comparing its absorbance (at 450 nm) with that of a known MDA–
BSA standard curve.
2.10. Protein oxidation
The OxiSelectTM Nitrotyrosine ELISA kit (Cell Biolabs, Inc., San Diego,
CA, USA) was used for detection and quantiﬁcation of 3-nitrotyrosine
(3-NT) in protein samples from mouse GL261 and normal brain tissue
lysates as a measure of protein oxidation. This nitrotyrosine quantiﬁca-
tion kit was a competitive ELISA. In brief, the unknown protein
nitrotyrosine samples or nitrated BSA standards were ﬁrst added to a
nitrated BSA pre-absorbed EIA (enzyme immunoassay) plate. After a
brief incubation, an anti-nitrotyrosine antibody was added, followed
by an HRP conjugated secondary antibody. The protein nitrotyrosine
content in unknown samples was determined by comparing with a
standard curve that was prepared from predetermined nitrated BSA
standards.
2.11. Statistical analyses
Statistical differences between the probe-administered and control
groups were analyzed with an unpaired, two-tailed Student t test
using commercially available software (InStat; GraphPad Software,
San Diego, CA, USA). A p value of less than 0.05 was considered to indi-
cate a statistically signiﬁcant difference.
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3.1. Experimental strategy
Fig. 1 illustrates the anti-DMPO and IgG isotype contrast agent con-
struct design, and depicts the experimental strategy for the in vivo
IST-mMRI studies. An anti-body–albumin–Gd-DTPA–biotin construct
was used for both the anti-DMPO probe and the non-speciﬁc IgG con-
trast agent isotype control. Initially, glioma-bearing mice were injected
(i.p.) with DMPO consecutively for 5 days (3 times daily) to trap free
radicals in glioma tissue, and then a tail-vein catheterwas used to obtain
molecular MR images of trapped DMPO-radical adducts that remained
in glioma tissue in glioma-bearing mice with an anti-DMPO probe.3.2. Anti-DMPO probe characterization in GL261 cells
Fig. 2 presents in vitro data regarding the effect of the anti-DMPO
probe on MRI signal intensity (SI) and T1 relaxation in oxidized GL261
glioma cells. GL261 cells that were oxidized with hydrogen peroxide,
subsequently administered DMPO to trap free radicals, and then ex-
posed to the anti-DMPOprobe,were found to have an increasedMR sig-
nal intensity and a corresponding decrease in T1 relaxation time,
compared to cells alone or oxidized cells with DMPO but without the
anti-DMPO probe. GL261 cells administered DMPO and the anti-
DMPO without hydrogen peroxide also had an increased SI and corre-
sponding decrease in T1 relaxation, and were found to be signiﬁcantlyA
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Fig. 2. In vitro assessment of the anti-DMPO probe in mouse GL261 glioma cells. (A) MRI signa
either (1) GL261 cells alone (in PBS), (2) GL261 cells + hydrogen peroxide (H2O2, abbreviated h
(GL + D + P), (4) GL261 cells + HP + DMPO + anti-DMPO probe (GL + HP + D + P), or
samples 1–5 described above. Values are represented as mean ± S.D. There was a signiﬁcan
DMPO probe compared to GL261 cells alone (p b 0.001), GL261 cells with HP and DMPO (p b
There was also a signiﬁcant decrease in T1 relaxation for samples containing GL261 cells +
water (‡p b 0.05), but not GL261 cells alone.different to vials containing GL261 cells + hydrogen peroxide +
DMPO or water alone, but not GL261 cells alone.
3.3. In vivo detection of free radicals in GL261 gliomas
Fig. 3 depicts increased uptake of the anti-DMPOprobe in glioma tis-
sue (Fig. 3A). By comparison, a non-speciﬁc IgG contrast agent was not
taken up in glioma tissue (Fig. 3B). GL261 glioma-bearing mice admin-
istered the anti-DMPO probewere found to have signiﬁcantly increased
changes in T1 relaxation (Fig. 3C; p b 0.001) and MR SI (Fig. 3D;
p b 0.001) in tumor regions compared to GL261 glioma-bearing mice
administered a non-speciﬁc IgG Gd-based contrast agent. The anti-
DMPO probe was also found to be signiﬁcantly higher (p b 0.001) in
tumor vs. contralateral tissues (Fig. 3C,D).
3.4. Conﬁrmation of presence of anti-DMPO in ex vivo GL261 glioma tissue
and co-localization with oxidative stress markers
A representativeMR image (T2-weighted) is shown in Fig. 4A, with a
histological image in a tumor region with necrosis (Fig. 4B). Fluores-
cence detection of the anti-DMPO probe was found to be elevated in
ex vivo glioma tissue (Fig. 4C). The ﬂuorescence agent Cy3 (green) at-
tached to streptavidin targets the biotin moiety of the anti-DMPO
probe that is present in ex vivo excised tumor tissue from a GL261
glioma-bearing mouse administered the anti-DMPO probe in vivo.
Comparatively, there wasn't any speciﬁc uptake of the IgG contrast
agent in gliomas administered the isotype control complex (Fig. 4D).GL+D+P GL+HP+D+P Water
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Fig. 3.mMRI detection of membrane-bound radical adducts in a GL261 mouse glioma model. (A) T2-weighted MR image with an overlaid difference threshold image (depicted as a red
region) (120 min post- and pre-administration of anti-DMPO probe) following administration of the anti-DMPO probe, taken at 30 days after intracerebral implantation of GL261 cells in
mice (n = 4). Note increased uptake of the anti-DMPO probe in the peripheral tumor region surrounding a necrotic lesion (depicted as a dark void). (B) T2-weighted MR image with an
overlaid difference threshold image (120 min post- and pre-administration of the IgG contrast agent) following administration of the IgG contrast agent, taken at 27 days after intrace-
rebral implantation of GL261 cells in mice (n = 4). Note no speciﬁc uptake of the IgG contrast agent in the tumor region. (C) Histogram of quantitative percent T1 changes in
tumor and contralateral (Contra) regions of GL261 glioma-bearingmice administered either the anti-DMPO probe (Anti-DMPO) or a non-speciﬁc IgG contrast agent (IgG). (D) Histogram
of quantitative percentMR signal intensity (SI) changes in tumor and contralateral (Contra) regions of GL261 glioma-bearingmice administered either the anti-DMPOprobe (Anti-DMPO)
or a non-speciﬁc IgG contrast agent (IgG).
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was also obtained for oxidative stress markers 3-NT (Fig. 4E) and 4-
HNE (Fig. 4F) in some areas of glioma tissue from GL261 glioma-
bearing mice administered DMPO and the anti-DMPO probe.3.5. Conﬁrmation of the presence of DMPO-trapped radicals in GL261
gliomas
GL261 glioma tissue from animals not administered the anti-DMPO
probe, but given DMPO, was assessed for the immunohistochemical or
ex vivo IST detection of DMPO-radical adducts. There was a detected in-
crease in level of IHC-stained DMPO nitrone adducts from ex vivo glio-
ma tissue (Fig. 5Ai and the increased magniﬁcation image in Aii),
compared to normal brain tissue (Fig. 5Bi and Bii).3.6. Detection of oxidized lipids and proteins in GL261 gliomas
Oxidized lipids (as commonly occurs with lipid peroxidation), mea-
sured by elevated malondialdehyde (MDA) protein adducts (pmol/mg
tissue protein) were found to be signiﬁcantly increased in ex vivo
GL261 glioma homogenates (p b 0.001) compared to normal mouse
brain tissue (Fig. 6A). Also 3-nitrotyrosine (3-NT) levels (nM/m tissue
protein), an indication of oxidized proteins, were found to be signiﬁ-
cantly increased in ex vivo GL261 glioma tissue (p b 0.05) compared
to normal brain tissue (Fig. 6B).
4. Discussion
After DMPO is administered, it binds to radicals to form radical ad-
ducts. It is thought that predominantly only radical adducts that are
C D
1
1 1
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1
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Fig. 4.Ex vivo detection of the anti-DMPOprobe and co-localizationwith oxidative stressmarkers. (A) Representative T2-weightedMR image of a GL261 glioma-bearingmouse brain,with
a marked region (red rectangle) depicting where a histology (H&E) slide (B) was obtained in a region with necrosis (×400 magniﬁcation). (C) Fluorescence image of streptavidin-FITC
(green) targeting the biotin moiety of the anti-DMPO probe in a GL261 glioma-bearing mouse. (D) Fluorescence image of streptavidin-FITC (green) which binds to the biotin moiety of
the IgG contrast agent in a GL261 glioma-bearingmouse. Note that ﬂuorescence levels are elevated in a GL261mouse administered the anti-DMPOprobe (C), but not the one administered
the non-speciﬁc IgG contrast agent (D). Immunohistochemistry images of 3-NT (E) or 4-HNE (F) (both green) co-localized with the presence of the anti-DMPO probe (red, streptavidin-
Cy3) in GL261 glioma-bearingmice administered DMPO and the anti-DMPO probe. Note co-localized areaswith both anti-DMPOprobe and either 4-HNE or 3-NT (orange, arrows used to
depict some examples). Representative necrotic areas in panels A–E are labeled with the number 1. Cell nuclei are stained blue (Dapi). Magniﬁcation bars are 50 μm.
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targeted by the Gd-based anti-DMPO probe (~232 kDa) and detected
by MRI. From another study using a similar probe construct to detect
in vivo levels of inducible nitric oxide synthase (iNOS), transmission
electronmicroscopy (TEM) was used to demonstrate that iNOSwas de-
tected within the plasma membrane in C6 rat glioma cells, and that an
anti-iNOS probe was able to detect in vivo levels of iNOS speciﬁcally in
glioma tissue [11]. Since the detected iNOS was within the plasma
membrane, it was speculated that some of the anti-iNOS probe was in-
ternalized into the plasmamembrane to allowmMRI detection.Wheth-
er the probe construct is internalized intracellularly would still need to
be established in future studies.mMRI relies on the speciﬁc labeling of extracellular cell surface re-
ceptors or antigens with a targeted contrast agent. The MRI contrast
agent probe is targeted to a speciﬁc receptor or antigen by an antibody
(Ab). These compounds alter proton magnetization relaxation times at
their sites of accumulation, making them ideal for diagnostic purposes.
Paramagnetic gadolinium (Gd)-based MR contrast agents generate a
positive signal contrast (T1 contrast) which enhancesMR signal intensi-
ties of water molecules that surround these agents in T1-weighted MR
images. Gadolinium (Gd)-based probes that bind to afﬁnity molecules,
have recently become popular when used with mMRI. Our laboratory
has previously usedmMRI methodology to provide in vivo evidence re-
garding the over-expression of various tumor markers [7,11–14] in
Ai
ii
ii
Bi
DMPO (normal)
DMPO (GL261)
Fig. 5. Ex vivo detection of DMPO nitrone adducts in GL261 gliomas. Immunohistochemistry or IST images of DMPO-adducts from excised brain tissues of either a GL261 glioma-bearing
mouse (Ai, and increasedmagniﬁcation image in Aii), or a normal mouse (Bi, and increasedmagniﬁcation image in Bii), both administeredDMPO (no anti-DMPOprobe). Enlarged images
shown in (ii) are taken from regions outlined in corresponding (i) images. Note elevated DMPO-adducts in the GL261 glioma (compared to normal brain tissue). Magniﬁcation bars in
images labeled “i” are 20 μm, and 5 μm for images labeled “ii”.
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(orthotopic C6 or RG2 gliomas) that the blood–brain-barrier is
disrupted allowing the albumin-Gd-based probes to enter glioma tissue
[11]. In theGL261mousemodel, it has been shown that there is BBBdis-
ruption, as revealed by confocal imaging of IgG leakage into tumor tis-
sue and surrounding brain parenchyma [15]. Due to the leaky BBB in
gliomas we have used a similar molecular imaging probe construct in
other glioma models to detect c-Met [7] and iNOS [11]. It is anticipated
that the low MW of DMPO (113.2) would also be able to reach the
tumor via a leaky BBB. Recently we used the same anti-DMPO probe
used in this study to assess radical formation in various tissues/organs
(e.g. liver, lungs and kidneys) within diabetic mice [16], indicating
the broad application of the anti-DMPO probe and mMRI in other
oxidative-stress-related diseases.
Gliomas comprise the majority of primary brain tumors diagnosed
annually in the United States (CBTRUS, 2011). Gliomas are classiﬁed
by theWorld Health Organization according to their morphologic char-
acteristics into astrocytic, oligodendroglial, and mixed tumors [17]. Ap-
proximately 15,000 patients die with glioblastomas in the U.S.A. per
year [18]. Due to the inﬁltrative nature of gliomas, surgery is rarely ef-
fective, i.e. after surgical removal tumors recur predominantly within
1 cm of the resection cavity [19]. Despitemodern diagnostics and treat-
ments the median survival time for patients with glioblastomas does
not exceed 15 months [19,20]. Prognosis is related not only to tumor
grade but to glioma subtype, i.e. oligodendrogliomas are characterized
by a better prognosis [17]. Other important hallmarks of malignant gli-
omas are their invasive behavior and angiogenesis [19].Oxidative stress plays a major role in the growth of gliomas. For in-
stance, the antioxidant status of glioma patients was found to be
lowered [21]. It has also been suggested that there is a link between
free radical generation and intra-mitochondrial cytochrome-c degrada-
tion, which could lead to the impairment of the apoptotic cytochrome-
c-dependent cascade [22]. In addition it has been found thatmanganese
superoxide dismutase is over-expressed in most brain tumors, leading
to the increased activation of mitogen-activated protein kinases and
phosphatidylinositol-3-kinases, which promote migration and invasion
in glioma cells [23]. Oxidative modiﬁcation of cell lipids and proteins
also has potential consequences for tumor cell proliferation [24]. In
this study, we detected in vivo elevated free radicals within mouse
GL261 gliomas with the use of an anti-DMPO probe. It is hypothesized
that major macromolecules, such as proteins and lipids, that are oxi-
dized by free radicals generated in gliomas are targeted by the anti-
DMPO probe. Supporting evidence of both oxidized lipids and proteins
in GL261 gliomas was provided from quantitative ex vivo studies on
GL261 glioma tissue, which indicated that there was signiﬁcantly in-
creased oxidized lipids (asmeasuredbyMDA-protein adducts) and pro-
teins (as measured by 3-NT) in tumors compared to normal mouse
brain tissue (Fig. 6). Qualitative co-localization of the anti-DMPO
probe with 4-hydroxynonenal (HNE), another marker for oxidized
lipids, or 3-NT, was detected in ﬂuorescence images from glioma-
bearing mice administered DMPO and the anti-DMPO probe (Fig. 4).
Other investigators have shown that in ethylnitrosourea (ENU)-induced
rat gliomas there are increased immunopositive histological regions for
HNE, MDA and nitrotyrosine (3-NT) which correlate with glioma
Fig. 6. Quantitative measure of the oxidation of macromolecules in ex vivo GL261 glioma
tumors. (A)MDA-protein adduct concentration (pmol/mg protein) in tissue homogenates
frommouse GL261 gliomas (n = 8) and normal brain (n = 4). Therewas a signiﬁcant in-
crease in MDA-adducts in GL261 mouse tumor tissue compared to normal brain samples
(***p b 0.001). (B) 3-Nitrotyrosine (3-NT) concentration (nM/mg protein) in tissue ho-
mogenates from GL261 gliomas (n = 6) and normal brain (n = 4). There is a signiﬁcant
increase in 3-NT from GL261 gliomas compared to normal brain (*p b 0.05).
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proteins may be trapped by DMPO and subsequently detected by IST-
mMRI detection with the anti-DMPO probe.
We also presented quantitative data supporting the increased afﬁn-
ity of the anti-DMPO probe for isolated GL261 glioma cells thatwere ex-
posed to the ROS agent, hydrogen peroxide, and in the presence of
DMPO and the anti-DMPO probe (Fig. 2), as well as GL261 cells exposed
to both DMPO and the anti-DMPO probe without hydrogen peroxide.
The exogenous hydrogen peroxide was added to ensure generation of
free radicals in the in vitro environment, and verify speciﬁc binding of
the anti-DMPO probe to glioma cells that generate free radicals. Addi-
tion of hydrogen peroxide to the GL261 cells in vitro did decrease T1 re-
laxation 1.7-fold more-so compared to no addition of hydrogen
peroxide. The in vitro results with hydrogen peroxide were similar to
the in vivo results in glioma tissue where there was a 2.9-fold decrease
in %T1 change. Perhaps in the in vivo tumor environment, hydrogenper-
oxide is being generated, which is being detected by DMPO trapping of
hydroxyl radicals generated fromhydrogen peroxide-mediated Fenton-
like chemistry. It may be possible that endogenous hydrogen peroxide
or subsequent free radicals generated from glioma cells in vitro maybe dispersed in the cell culture media. It is interesting to point out that
there is evidence that hydrogen peroxide is involved in the promotion
ofmigration and invasion in glioma cells (U87) viamanganese superox-
ide dismutase [23,26]. It has also been established that some glioma cell
lines (e.g. U373MG) which have a mutated p53, are resistant to hydro-
gen peroxide induced cell death [27]. As related to this study, it should
also be noted that mouse GL261 cells carry a point mutation in the
p53 gene [28], allowing increased hydrogen peroxide to be produced
which may play a role in the aggressive nature of these tumor cells.
Several studies have used IST in ex vivo tissues to detect DMPO-
radical adducts [2,4,5]. Protein radicals trapped by DMPO to form
DMPO-protein radical adducts, for example, were studied by Ramirez
et al. [4] utilizing IST to detect oxidized-super oxide dismutase 1.
Other studies also support increased lipid and protein oxidation in glio-
mas. Lipid peroxidation, asmeasuredby increased levels of HNE-protein
adducts by IHC, was found to be signiﬁcantly increased in astrocytic
(120 patient samples) and ependymal (40 samples) human glial tu-
mors, andwas proportionally elevated in tumors that weremoremalig-
nant or had increased neovascularization [29]. HNE levels are found to
be elevated in high-grade astrocytomas and glioblastomas [30,31].
HNE levels are particularly important as this signaling molecule is
known to act as a growth-regulating factor [30].
An advantage of the IST approach coupledwithmMRI is that hetero-
geneous tissues, such as tumors, can be studied to obtain spatial differ-
ences in the detection of free radical levels (detected by the presence of
the anti-DMPO probe via coupling to DMPO-radical nitrone adducts). In
this study, we were able to show that free radical adducts are mainly
distributed in localized peripheral tumor regions near necrotic regions
(Fig. 3A). In other studies on either rat F98 gliomas [32] or rat 9L
gliosarcomas [33], positron emission tomography (PET) was used to
demonstrate that increased 18F-ﬂuorodeoxy glucose (FDG) uptake
was found to occur mainly in peripheral tumor regions. 18F-FDG
which is often used to study glucose uptake, has also previously
shown an association with cell proliferation. For instance, 18F-FDG has
been found to be a suitable marker to assess PI3K inhibitors, where
the PI3K oncogenic signaling pathway is involved with the regulation
of multiple cellular processes including glucose metabolism, prolifera-
tion and cell survival [34]. The ex vivo ﬂuorescence data (Fig. 4) indi-
cates that the anti-DMPO-probe is distributed mainly in tumor regions
with increased cell proliferation surrounding necrotic lesions. Ex vivo
IST of mice administered DMPO only, conﬁrms the presence of DMPO-
radical adducts in gliomas (Fig. 5).
There are other imagingmethods that have been used to detect rad-
icals, including ESR, ﬂuorescence imaging or Overhauser-enhancedMRI
(OMRI). OMRI potentially offers a potential method of detecting low
concentrations of free radical species generated by speciﬁc biological
processes; however spatial resolution and general radical detection
are limited [35]. 3D-OMRI currently is mainly used to detect injected
free radicals (1-oxyl-2,2,5,5-tetramethyl-2,5-dihydro-1H-pyrrole-3-
carboxylic acid, or TOPCA), and this technique was used in rats bearing
C6 brain-implanted gliomas [35]. Although ESR imaging is sensitive, it
lacks the image resolution of MRI and is often limited to the detection
of an injected paramagnetic probe at the injection site. However, it
should benoted that this technique has been used to detect in vivo nitric
oxide in ischemic tissues [36] and lipopolysaccharide exposed mice
[37]. The disadvantage of ﬂuorescence imaging is that it is restricted to
excised tissues or isolated cells.
5. Conclusions
Here we used a combination of mMRI and IST to show for the ﬁrst
time the non-invasive in vivo quantitative detection of free radicals
in mouse gliomas. Using both mMRI and IST provides the advantage
of in vivo image resolution and spatial differentiation of regional events
in heterogeneous tissues or organs and the regional targeting of
free radical mediated oxidation of cellular components, such as
2161R.A. Towner et al. / Biochimica et Biophysica Acta 1832 (2013) 2153–2161membrane-associated proteins and lipids. Qualitative ﬂuorescence data
for the presence of the anti-DMPO probe, as well as ﬂuorescence IST
data for the presence of DMPO-radical adducts, veriﬁes that the
in vivo approach is feasible. A correlation between the presence of the
anti-DMPO probe and oxidized lipids or proteins also supports the abil-
ity of the anti-DMPO probe to detect free radical associated processes.
This method can be applied towards any cancer for the in vivo assess-
ment of macromolecular free radical levels.
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